Abstract
Get full access to this article
View all access options for this article.
References
1.WTO and the TRIPS Agreement, www.who.int/medicines/areas/policies/wto_trips/en/ (accessed 20 April 2016) .
2.TRIPS, pt. II, § 5, Art. 27(1) .
3.Sherman et al. Pandemics & panaceas: the World Trade Organization’s efforts to balance pharmacuetical patents and access to AIDS drugs. Am Bus LJ 2004; 41: 358–411, 364 .
4.The WTO in brief: part 2, the organization, www.wto.org/english/thewto_e/whatis_e/inbrief_e/inbr02_e.htm (accessed 20 April 2016) .
5.TRIPS, pt. II, § 5, Art. 33 .
6.TRIPS, pt. II, § 5, Art. 27(1)(a) .
7.TRIPS, pt. II, § 5, Art. 27(2) .
8.41 Am Bus LJ 353, 368 .
9.TRIPS, pt. VII, Art. 70(8) .
10.TRIPS, pt. II, § 5, Art. 27(3) .
11.41 Am Bus LJ 369 .
12.TRIPS, pt. II, § 5, Art. 31(a)–(l) .
13.TRIPS, pt. II, § 5, Art. 31(b) .
14.41 Am Bus LJ 358–59 .
15.41 Am Bus LJ 359 .
16.41 Am Bus LJ 366 .
17.Declaration on the TRIPS Agreement and Public Health, WTO Ministerial Conference, 4th Sess., http://www.wto.org/english/theWTO_e/minist_e/min01_e/mindecl_trips_e.htm (accessed 20 April 2016) .
18.41 Am. Bus. L.J. 359: 367 .
19.Compulsory Licensing of Pharmaceuticals and TRIPS, www.wto.org/english/tratop_e/trips_e/public_health_faq_e.htm (accessed 20 April 2016) .
20.WTO members agree to extend drug patent exemption for poorest members, www.wto.org/english/news_e/news15_e/trip_06nov15_e.htm (accessed 6 November 2015) .
21.Least-Developed Countries, www.wto.org/english/thewto_e/whatis_e/tif_e/org7_e.htm (accessed 20 April 2016) .
22.Quadir. Patent Stalemate? The WTO’s essential medicines impasse between pharmas and least developed countries. Rutgers L Rev 2009; 61: 437–469, 446 .
23.61 Rutgers L Rev. 437, 446 .
24.61 Rutgers L Rev 437, 439 .
25.61 Rutgers L Rev 437, 445 .
26.61 Rutgers L Rev 437, 459 .
27.Thailand to Import Generic Version of Hearth Drug Plavix from India, www.finanznachrichten.de/nachrichten-2007-08/8869650-thailand-to-import-generic-version-of-heart-drug-plavix-from-india-020.htm (accessed 22 August 2007) .
28.61 Rutgers L Rev 437, 461 .
29.61 Rutgers L Rev 437, 461 .
30.61 Rutgers L Rev 437, 461 .
31.Lee. Can incentives to generic manufacturers save the Doha declaration’s paragraph 6. Georgetown J Int’l Law 2013; 1387–1420, 1417–1418 .
32.TRIPS, § 5, Art. 31(c) .
33.Beall et al. “Trends in compulsory licensing of pharmaceuticals since the Doha declaration: a database analysis” Plos Med. Epub ahead of print 10 January 2012. DOI: 10.1371/journal/pmed.10001154 .